Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: February 2022
-
The Federal Circuit Bar Association (FCBA) will be offering a remote program entitled "Building, Leveraging, and Enforcing IP Portfolios, Taking Diverse Perspectives into Account" on February 17, 2022 from 12:00 pm to 1:00 pm (ET). Patrick C. Keane of Buchanan Ingersoll & Rooney PC; Shawn Cage of Buchanan Ingersoll & Rooney PC (moderator); Isabella Fu…
-
J A Kemp will be offering a webinar entitled "Update on Plausibility" on February 22, 2022 from 4:00 pm to 5:00 pm (GMT). Ravi Srinivasan and Guy Brain of J A Kemp will cover recent developments in the assessment of whether a "plausible" disclosure of efficacy is present in the application as filed, including a…
-
By Kevin E. Noonan — On December 3rd, Junior Party the Broad Institute, Harvard University, and MIT (collectively, Broad) filed its Contingent Preliminary Motion No. 2 in Interference No. 106,133 (which names Sigma-Aldrich as Senior Party), asking the Patent Trial and Appeal Board to add claims 52-54 of Broad Application No. 16/177,403 to the interference,…
-
By Michael Borella — Mentone sued Digi for alleged infringement of Mentone's U.S. Patent No. 6,952,413. The U.S. District Court for the District of Delaware found the claims of the patent to be ineligible under 35 U.S.C. § 101. Mentone appealed. The invention of the '413 patent is directed to improvements in the allocation of…
-
By Kevin E. Noonan — The Patent Trial and Appeal Board heard oral argument under 37 C.F.R. § 41.124(c) on February 4th in the Priority Phase of Interference No. 106,115 between the Broad Institute, Harvard University, and MIT (collectively, "Broad") as Senior Party and the University of California/Berkeley, the University of Vienna, and Emmanuelle Charpentier…
-
By Donald Zuhn — Last month, Sen. Thom Tillis (R-NC), the Ranking Member of the Subcommittee on Intellectual Property of the Senate Committee of the Judiciary, wrote to the Administrative Conference of the United States (ACUS) to request that the agency "conduct a study on whether Congress should create a unified, stand-alone, and independent Intellectual…
-
February 8, 2022 – European biotech patent law update (D Young & Co) – 9:00 am, noon, and 5:00 pm (GMT) February 15, 2022 – "The Expanding Reach of the Abstract Idea — What Is and Is Not Patentable Eight Years After Alice" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am…
-
McDonnell Boehnen Hulbert & Berghoff LLP will be offering a live webinar entitled "The Expanding Reach of the Abstract Idea — What Is and Is Not Patentable Eight Years After Alice" on February 15, 2022 from 10:00 am to 11:15 am (CT). In this presentation, MBHB attorney and Patent Docs author Michael Borella will review…
-
IPWatchdog and ClearstoneIP will be offering a webinar entitled "The Modern FTO Framework: Strategies for Connected, Risk-Reduced Innovation" on February 17, 2022 at 11:00 am (EST). Rich Roberson of adidas, Lisa Adams of Mintz, Gabe Sukman of ClearstoneIP, and Gene Quinn of IPWatchdog, Inc. will address the practical mechanics of freedom-to-operate investigations to achieve responsive…
-
By Kevin E. Noonan — On Wednesday, the U.S. Food and Drug Administration announced approval to Mylan Pharmaceuticals for a generic form of Allergan's RESTASIS® (Cyclosporine Ophthalmic Emulsion 0.05%) product for treatment of chronic dry eye. RESTASIS® is "a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients whose tear production is presumed to…
Patent Docs 